津药药业股份有限公司 关于天津医药集团财务有限公司的 风险持续评估报告 1 / 8 财务公司经营范围： 吸收成员单位存款；办理成员 单位贷款；办理成员单位票据贴现；办理成员单位资金结 算与收付；提供成员单位委托贷款、债券承销、非融资性 保函、财务顾问、信用鉴证及咨询代理业务；从事同业拆 借；办理成员单位票据承兑；除股票投资以外类有价证券 投资。 按照《上海证券交易所上市公司自律监管指引第 5 号 —交易与关联交易》的要求，津药药业股份有限公司（以 下简称"公司"）通过查验天津医药集团财务有限公司（以 下简称"财务公司"）的《营业执照》与《金融许可证》 等证件资料，并审阅了包括资产负债表、利润表、现金流 量表等在内的财务公司的定期财务报告，对其经营资质、 业务和风险状况进行了评估，现将有关风险评估具体情况 报告如下： 一、天津医药集团财务有限公司基本情况 财务公司经原中国银行保险业监督管理委员会批准， 于 2016 年 9 月正式成立，由天津市医药集团有限公司、津 药达仁堂集团股份有限公司、天津力生制药股份有限公司、 天津药业集团有限公司和天津金益投资担保有限责任公司 共同出资，注册资本金 5 亿元人民币。 注 ...

证券代码：600488 证券简称：津药药业 编号：2023-052 津药药业股份有限公司 （1）公司 2023 年半年度报告编制和审议程序符合法律、法规、《公 司章程》和公司内部管理制度的各项规定。 （2）2023 年半年度报告的内容和格式符合中国证监会和上海证券 交易所的各项规定，所包含的信息能从各个方面真实地反映出公司 2023 年半年度的经营管理和财务状况。 （3）监事会未发现参与 2023 年半年度报告编制和审议的人员有违 反保密规定的行为。 《公司 2023 年半年度报告》具体内容详见上海证券交易所网站 （www.sse.com.cn）公告。 表决结果：同意票 5 票，反对票 0 票，弃权票 0 票。 2.审议通过关于计提减值准备的议案。 第八届监事会第二十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）第八届监事会第二十二 次会议于 2023 年 8 月 29 日以通讯表决方式召开，会议通知已于 2023 年 8 月 17 日以电子邮件的方式送达公司 ...

天津长实律师事务所 关于津药药业股份有限公司股权激励限制性股票 回购注销的法律意见书 长实律见字【2023】56-1 号 CHANG SHI LAW FIRM 天津长实律师事务所 天津市河西区宾水道 11 号宾泰公寓 C-1801 电话： 022-28363638 传真： 022-28363638 cated and and the sent to the start to the start to the start to the series the RM ChangshiLaw Firm 天津长实律师事务所 关于津药药业股份有限公司股权激励限制性股票 回购注销的法律意见书 长实律见字【2023】56-1号 致:津药药业股份有限公司 根据《公司法》、《证券法》、中国证券监督管理委员会发布的《上市公司股权激 励管理办法(试行)》(以下简称"《管理办法》")、《国有控股上市公司(境内) 实施股权激励试行办法》、《关于规范国有控股上市公司实施股权激励制度有关问题的 通知》及其他有关法律、法规、规范性文件的相关规定,天津长实律师事务所(以下简 称"本所"）接受津药药业股份有限公司（以下简称"公司"或"津药药业"） ...

证券代码：600488 股票简称：津药药业 编号：2023-050 津药药业股份有限公司 股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购注销原因：根据公司《限制性股票计划（草案二次修订稿）》 中相关条款的规定，鉴于 2022 年度公司层面业绩未达到限制性股票 激励计划设定的考核要求，公司限制性股票激励计划第二个解锁期解 锁条件未成就，公司将对股权激励计划第二个解锁期限制性股票共计 2,046,000 股进行回购注销；同时鉴于激励对象中 8 名激励对象因退 休等原因已不符合激励条件，公司将对其已获授但尚未解除限售的限 制性股票共计 264,000 股进行回购注销。以上合计 2,310,000 股。 本次回购注销限制性股票的有关情况 | 回购限制性股票股份数量 | 注销限制性股票股份数量 | 限制性股票注销日期 | | | | | --- | --- | --- | --- | --- | --- | | 2,310,000 股 | 2,310,000 股 | 202 ...

证券代码：600488 股票简称：津药药业 编号：2023-028 津药药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间：2023年5月17日(星期三)下午15:00-16:30 ●会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心视频直播和网络互动 ●投资者可于2023年5月10日(星期三)至5月16日(星期二)16:00前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （tjpc600488@vip.sina.com）进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 津药药业股份有限公司（以下简称"公司"）已于2023年3月30 日发布公司2022年年度报告，为便于广大投资者更全面深入地了解公 司2022年度经营成果、财务状况，公司计划于2023年5月17日下午 15:00-16:30举行2022年度业绩说明会，就 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 990,540,207.94, representing an increase of 11.33% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 67,479,421.90, a significant increase of 199.30% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 65,625,537.56, up 214.97% year-on-year[4]. - Basic earnings per share were CNY 0.062, reflecting a growth of 195.24% year-on-year[4]. - Net profit for Q1 2023 was ¥86,684,786.16, significantly up from ¥20,198,171.72 in Q1 2022, marking a growth of 329.5%[15]. - The net profit attributable to the parent company for Q1 2023 was ¥67,479,421.90, compared to ¥22,545,650.89 in Q1 2022, representing a significant increase[16]. - The total comprehensive income for Q1 2023 was ¥87,413,663.40, up from ¥21,422,002.25 in Q1 2022[16]. - The basic and diluted earnings per share for Q1 2023 were both ¥0.062, compared to ¥0.021 in Q1 2022, indicating a substantial improvement[16]. Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 182,559,986.10, an increase of 157.12% compared to the previous year[4]. - Cash inflows from operating activities for Q1 2023 totaled ¥854,021,932.28, compared to ¥676,987,593.44 in Q1 2022, reflecting a growth of approximately 26.1%[20]. - The net cash flow from operating activities for Q1 2023 was ¥182,559,986.10, significantly higher than ¥71,001,771.81 in Q1 2022[20]. - Cash and cash equivalents at the end of Q1 2023 amounted to ¥634,376,254.46, compared to ¥238,026,479.93 at the end of Q1 2022, showing a strong increase[21]. - The company incurred a net cash outflow from investing activities of ¥27,561,016.64 in Q1 2023, compared to a larger outflow of ¥54,822,833.34 in Q1 2022[21]. - The net cash outflow from financing activities for Q1 2023 was ¥127,834,883.84, contrasting with a net inflow of ¥13,204,190.02 in Q1 2022[21]. - The company received cash from borrowings amounting to ¥56,000,000.00 in Q1 2023, down from ¥80,404,449.66 in Q1 2022[21]. - The company reported a decrease in other cash received related to financing activities, totaling ¥0.00 in Q1 2023, compared to ¥105,000,000.00 in Q1 2022[21]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,621,276,388.42, a decrease of 0.44% from the end of the previous year[4]. - The total assets of the company as of March 31, 2023, were ¥6,621,276,388.42, a slight decrease from ¥6,650,699,943.31 at the end of 2022[13]. - Total liabilities decreased to ¥2,778,280,934.91 in Q1 2023 from ¥2,896,862,345.04 in Q4 2022, a reduction of 4.1%[13]. - The equity attributable to shareholders increased to CNY 3,042,515,751.08, up 2.36% from the end of the previous year[4]. - The company's total equity as of March 31, 2023, was ¥3,842,995,453.51, compared to ¥3,753,837,598.27 at the end of 2022, indicating an increase of 2.4%[13]. Research and Development - The subsidiary Tianjin Jinyao Pharmaceutical Co., Ltd. received approval for clinical trials of a new inhalation powder for COPD, indicating ongoing R&D efforts[9]. - The company’s product Furosemide Injection is expected to be selected in the eighth batch of national drug centralized procurement, which could enhance market share and brand influence[10]. - Research and development expenses increased to ¥46,733,026.35 in Q1 2023, up from ¥33,062,281.74 in Q1 2022, reflecting a growth of 41.5%[15]. Regulatory and Compliance Issues - The company faced administrative penalties totaling CNY 27,721,311.36 and CNY 29,884,312.48 for its subsidiaries, which will impact the 2022 profits[10].

Financial Performance - The company reported a total distributable profit of ¥856,451,168.44 as of December 31, 2022, with a proposed cash dividend of ¥0.10 per 10 shares, amounting to a total cash distribution of ¥10,963,626.80, resulting in a cash dividend payout ratio of 30.97%[4]. - The company achieved operating revenue of CNY 3.689 billion in 2022, a decrease of 1.59% compared to 2021[24]. - The net profit attributable to shareholders was CNY 35.41 million, down 27.25% from the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 203.92% to CNY 113.05 million[24]. - The basic earnings per share decreased by 28.89% to CNY 0.032, while the diluted earnings per share remained the same[22]. - The net cash flow from operating activities increased by 106.23% to CNY 653.52 million, driven by improved management of customer payment terms[23]. - The total assets increased by 4.82% to CNY 6.651 billion at the end of 2022[24]. - The company reported a total of 980,000 shares repurchased, with a total value of 686,000, resulting in a decrease of 294,000 shares[153]. Corporate Governance - The company emphasizes the importance of the accuracy and completeness of the annual report, with all board members present at the meeting[7]. - The company has a robust corporate governance structure, with independent boards and committees operating under legal and regulatory frameworks[148]. - The company has revised its governance policies to enhance compliance and reduce governance risks, ensuring timely and accurate information disclosure[146]. - The company has maintained a cash dividend policy since 2003, ensuring reasonable returns to investors annually[173]. - The company has a comprehensive assessment process for determining the remuneration of its directors and senior management[160]. - The company has established a remuneration committee to oversee the compensation of its directors and senior management[160]. - The company reported a total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.56 million yuan[160]. Risk Management - The company has provided a detailed analysis of potential risks in its report, particularly in the section discussing future developments and risks[6]. - The company is focusing on enhancing its marketing capabilities and risk awareness in compliance operations to strengthen market adaptability[39]. - The company is committed to strengthening project risk management to reduce the risks associated with new product development, thereby improving the success rate of R&D projects[139]. - The company is actively involved in risk assessment related to financial operations, ensuring compliance and stability[167]. Research and Development - Total R&D investment reached 183.19 million yuan, which is 4.97% of operating revenue, with 22.12% of the R&D costs capitalized[63]. - The company employed 500 R&D personnel, making up 19.46% of the total workforce[64]. - The company has several new drug developments in progress, including XP0020 for hypertension and XP0019 for autoimmune diseases, both classified as Class 3 chemical drugs and currently under review[92]. - The company is focusing on consistency evaluation for various products, including dexamethasone tablets, to ensure quality and efficacy in the market[89]. - The company is actively pursuing international registrations for its products, enhancing its global market presence and competitiveness[93]. Environmental Responsibility - The company invested 30.13 million yuan in environmental protection during the reporting period[187]. - The company has implemented real-time monitoring of environmental indicators through its SCADA data management platform to ensure compliance with environmental standards[140]. - The wastewater treatment facility operates normally, with average COD discharge at 177.731 mg/L, well below the standard limit of 500 mg/L[193]. - The company has established an emergency response plan for environmental incidents, with no incidents reported during the year[196]. - The company aims to continuously lower the incidence of workplace injuries and enhance employee safety through comprehensive training[188]. Market Position and Strategy - The company achieved a market share leadership in the U.S. for methylprednisolone acetate, with its first sterile lyophilized powder injection product successfully launched in the U.S. market[33]. - The company plans to actively develop new markets and continuously launch new products to enhance competitiveness[74]. - The company aims to become a leader in the steroid hormone and amino acid sectors, focusing on high-end product development and market expansion in both domestic and international markets[131]. - The company is committed to advancing its technology in the fields of steroid and amino acid drugs, focusing on the development of sterile raw materials and innovative formulations[132]. Operational Efficiency - The company implemented lean manufacturing principles, establishing nine cost-reduction targets to enhance operational efficiency and product yield[35]. - The company has established a talent pool and optimized performance assessment methods to enhance management efficiency and employee motivation[38]. - The company has achieved significant recognition, including being a national high-tech enterprise and the president unit of the National Steroid Hormone Industry Association[42]. - The company is addressing raw material price risks by enhancing supplier selection and procurement strategies to mitigate cost impacts[136]. Shareholder Engagement - The company held a total of 26 board meetings during the reporting period, with all directors attending the meetings as required[165]. - The company approved various proposals in shareholder meetings, including the initiation of foreign exchange derivative trading and amendments to the company’s articles of association[149]. - The company reported a reduction in shareholdings for several executives due to stock repurchase programs, with specific reductions of 48,000 shares for the acting chairman and 36,000 shares for the deputy general manager[151].